Skip to Content

Naftifine topical Pregnancy and Breastfeeding Warnings

Naftifine topical is also known as: Naftin, Naftin-MP

Naftifine topical Pregnancy Warnings

Animal studies have failed to reveal evidence of embryofetal toxicity or teratogenicity. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Use is recommended only if clearly needed and the benefit outweighs the risk to the fetus.

US FDA pregnancy category: B

See references

Naftifine topical Breastfeeding Warnings

Caution is recommended; application to the nipple area should be avoided.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-Considered a low risk to the nursing infant since only 4% to 6% is absorbed after topical application.
-The infant's skin should not come into direct contact with skin that has been treated.

See references

References for pregnancy information

  1. "Product Information. Naftin (naftifine topical)" Merz Pharmaceuticals, Greenboro, NC.
  2. "Product Information. Naftin (naftifine topical)" Merz Pharmaceuticals, Greensboro, NC.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Naftin (naftifine topical)" Merz Pharmaceuticals, Greenboro, NC.
  3. "Product Information. Naftin (naftifine topical)" Merz Pharmaceuticals, Greensboro, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide